NHS in England to start prescribing weight-loss jab Wegovy despite low supply | Obesity

  • Post category:Health
  • Post comments:0 Comments

The load-loss drug Wegovy is being made obtainable within the UK as a part of a “controlled and limited launch”.

The drug, also referred to as semaglutide, will likely be prescribed by way of specialist NHS weight administration companies alongside a decreased calorie food regimen and train from 4 September.

These eligible ought to have a physique mass index (BMI) of greater than 30 and a minimum of one weight-related co-morbidity.

The Nationwide Institute for Care and Excellence (Good) gave Wegovy the inexperienced mild for NHS use earlier this 12 months.

Its steering mentioned it needs to be used for a most of two years.

Wegovy producer Novo Nordisk mentioned it believed the launch of the drug within the UK “will help provide an additional option to support people living with obesity”.

In June, the federal government introduced a £40m pilot to increase entry to weight-loss jabs to sort out weight problems.

Talking on the time, Prime Minister Rishi Sunak mentioned the drug might be a game-changer”.

“Obesity puts huge pressure on the NHS,” he mentioned. “Using the latest drugs to support people to lose weight will be a game-changer by helping to tackle dangerous obesity-related health conditions such as high blood pressure, diabetes and cancer – reducing pressure on hospitals, supporting people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists.”

Nonetheless, Novo Nordisk has since confirmed semaglutide is in brief provide and mentioned it anticipated it “to be constrained for the foreseeable future”.

A “proportion of available supply” has been allotted to NHS companies.

“We will continue to work with healthcare professionals to help ensure that patients with the highest unmet medical need are prioritised,” the corporate mentioned.

“We are closely monitoring Wegovy demand and are working with regulators and providers to ensure people living with obesity can have access to and remain on treatment.”

An NHS spokesperson mentioned: “Despite global supply constraints, NHS England is taking action to begin implementing Nice guidance for weight management, while at the same time working to restore supplies of this class of drug for people with type 2 diabetes.

“Around 50,000 eligible patients in England could be prescribed Wegovy through NHS specialist weight management services, that are able to provide appropriate multidisciplinary care.”

It comes after a five-year by research by Novo Nordisk, referred to as the Choose trial, discovered the drug might minimize the danger of a coronary heart assault or stroke in overweight individuals with heart problems by a fifth.

It included 17,604 adults over the age of 45 from throughout 41 international locations, every with a BMI of greater than 27 and established heart problems, with no historical past of diabetes.

Source Link

Spread the love

Leave a Reply